deciphera®
a member of
ONO PHARMA

Dellann Elliott Mydland
The End Brain Cancer Initiative | Chris Elliott Fund
16150 NE 85th St., Suite #201
Redmond, WA. 98052

October 6th, 2025

To Whom It May Concern,

It is with admiration and respect that I write this letter of recommendation for the **End Brain Cancer Initiative (EBCI)**, a pioneering organization whose commitment to the neuro-oncology space—particularly for patients diagnosed with **Primary Central Nervous System Lymphoma (PCNSL)**has helped transform the landscape of advocacy, education, and clinical engagement for this underserved patient population.

EBCI's work is grounded in a philosophy of **listening first**—a belief that real change begins when patients and care partners are heard. Their partnerships with industry, researchers, and healthcare providers reflect a collaborative spirit that is essential to innovation in rare cancer care. One way this was demonstrated was through the PCNSL **national survey and patient & care partner focus group initiative**, conducted in partnership with Deciphera/Ono Pharma. The survey results allowed EBCI to identify the emotional, cognitive, and informational challenges faced by this rare-cancer community. These findings revealed critical gaps in support, including the need for resources, educational materials, and tools to help patients and caregivers navigate complex medical information. These insights have directly informed the development of tailored resources and advocacy strategies that meet the community's needs.

Beyond education and support, EBCI has been a catalyst for clinical trial engagement, working to close the gap between diagnosis and information about advanced treatments. Their collaboration exemplifies their dedication to ensuring that patients with rare CNS tumors, including PCNSL, are educated about clinical trials and therapies. EBCI's advocacy for inclusive clinical trial protocols and their emphasis on patient-centered decision-making help shape more equitable and responsive research frameworks.

EBCI's dedication to understanding and addressing the unmet needs of the PCNSL community, combined with their strategic engagement in clinical research and advocacy, makes them an invaluable partner in the pursuit of better outcomes and quality of life for all those impacted by brain cancer.

Sincerely,

Thomas Lechner

Dr. Thomas Lechner, MSc, PhD
VP, Medical Affairs